

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTDate Submitted: DEC 01 2005  
(use as many sheets as necessary)

Sheet 1 of 2

## Complete if Known

Application Number	10/553,298
Filing Date	10/14/2005
First Named Inventor	Nicholas BARDEN
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	028622-0137

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
A1	2004/0229262	A1		FRANCO et al.	11/18/2004	
A2	6,214,581	B1		LYNCH et al.	04/10/2001	

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	A3	EP	1199372	A2	ASTRAZENECA AB	04/24/2002		
	A4	EP	1310493	A1	PFIZER PRODUCTS, INC.	05/14/2003	= A8	
	A5	WO	99/55901	A	ABBOTT LABORATORIES	11/04/1999		
	A6	WO	01/44213	A	ASTRAZENECA AB	06/21/2001		
	A7	WO	01/62787	A1	OXFORD GLYCOSCIENCES (UK) LIMITED	08/30/2001		
	A8	WO	03/42190	A	PFIZER PRODUCTS INC.	05/22/2003	= A4	

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>3</sup>
A9	BURNSTOCK, Geoffrey,	"Introduction: P2 Receptors," Current Topics in Medicinal Chemistry, Vol. 4, 2004, pp. 793-803.	
A10	HUMPHREYS et al.,	"Isoquinolines as Antagonists of the P2X <sub>2</sub> ; Nucleotide Receptor: High Selectivity for the Human versus Rat Receptor Homologues," Molecular Pharmacology, Vol. 54, 1998, pp. 22-32.	
A11	LIU et al.,	"Technological Advances in High-Throughput Screening," Am. J. Pharmacogenomics, Vol. 4, No. 4, 2004, pp. 263-276.	
A12	MUZYNY et al.,	"Homo sapiens 12 BAC RP 11-946P6 (Roswell Park Cancer Institute BAC Library) complete sequence," December 2, 2002, XP002284283 (Database EMBL, 5/14/1999, Database Accession No. AC007546).	
A13	NORTH et al.,	"Pharmacology of clones P2X receptors," Annual Review of Pharmacology and Toxicology, Vol. 40, 2000, pp. 563-580.	
A14	SANZ et al.,	"Tenidap enhances P2Z/P2X <sub>2</sub> receptor signaling in macrophages," European Journal of Pharmacology, Vol. 355, 1998, pp. 235-244.	
A15	SILVERMAN, Richard B.,	The Organic Chemistry of Drug Design and Drug Action, Second Edition, Elsevier Academic Press, Chapter 2, pp. 7-120.	
A16	WILLIAMS, Michael,	"Purine Drugs: Opportunities in the 1990s," Drug Development Research, Vol. 28, 1993, pp. 438-444.	

Examiner  
Signature

/Michael Pak/

Date  
Considered

01/05/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

VASH\_1482272.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MP/